Skip to main content

Table 1 Main characteristics of the included studies in this meta-analysis

From: Increased CD9 expression predicts favorable prognosis in human cancers: a systematic review and meta-analysis

Study Country Cancer type Sample size Sex of patients (male
/female)
Mean or median age (years) Study period Mean or median follow-up (months) Clinical outcome CD9
detection
Cut-off value of
CD9 expression
Survival analysis NOS
Baek et al. [6] South Korea Invasive lobular carcinoma 113 NA 48 (27–88) 2001–2013 62 (7–187) DFS IHC Staining scores with intensity and proportion (≥ 4) MVA 8
Touzet et al. [7] France Acute myeloid leukemia 112 61/51 51.9 (20.9–77.6) 2009–2016 NA OS, RFS Flow cytometry 20% of all the blasts UVA(OS) MVA(RFS) 7
Liang et al. [22] China Acute lymphoblastic leukemia 112 48/64 39.46 2013–2016 NA OS Flow cytometry 20% of all the blasts MVA 7
Kwon et al. [21] South Korea Invasive breast cancer 1349 NA NA 1995–2007 115 (1–233) DFS IHC Staining scores with intensity and proportion (4) MVA 8
Kim et al. [10] South Korea Colorectal carcinoma 304 163/141 NA 1996–2000 4–243 DFS IHC Staining scores with intensity and proportion (3) MVA 8
Dong et al. [20] China Follicular lymphoma 76 32/44 50.90 (25–76) 2006–2013 NA PFS IHC Staining scores with intensity and proportion (3) UVA 6
Amatya et al. [19] Japan Malignant mesothelioma 112 103/9 65.8 (42–88) NA 16.5 (0–79) OS IHC Negative: no staining MVA 8
Zou et al. [13] China Gallbladder adenocarcinoma 108 24/84 52.6 (35–70) 1996–2006 NA OS IHC 25% MVA 7
Mhawech et al. [15] Switzerland Head and neck squamous cell carcinoma 153 122/31 59 (35–90) 1992–1999 65 (14–123) DFS IHC 50% MVA 8
Hashida et al. [11] Japan Colon cancer 146 84/62 62.8 (35–80) 1994–2001 44.3 (6.3–85.9) OS, DFS IHC Staining scores with intensity and proportion (120) MVA 8
Erovic et al. [16] Austria Head and neck squamous cell carcinoma 34 27/7 56 (42–77) 1985–2001 0–92 OS, DFS IHC 50% UVA(OS)
MVA(DFS)
8
Mhawech et al. [18] Switzerland Urothelial bladder carcinoma 320 257/63 70.4 (27–98) 1988–1999 43.6 (112–240) RFS IHC 5% MVA 8
Shimada et al. [12] Japan Eaophageal squamous cell carcinoma 116 98/18 63.9 1987–1995 5.69 OS IHC 50% MVA 8
Huang et al. [9] Japan Breast cancer 109 NA NA 1987–1995 48.5 OS, DFS RT-PCR Positive/Negative MVA 8
Sho et al. [14] Japan Pancreatic cancer 40 31/9 66 (47–80) 1992–1997 22.9 (5–62) OS RT-PCR Positive/Decreased MVA 8
Miyake et al. [8] Japan Breast cancer 143 NA NA 1990–1992 45.7 (30–61) OS, DFS IHC 50% MVA 8
Higashiyama et al. [17] Japan Non-small cell lung cancer 109 80/29 NA 1991–1992 43.7 (31–55) OS RT-PCR Positive/Negative MVA 8
  1. DFS disease-free survival, IHC immunohistochemistry, MVA multivariate analysis, NA not available, NOS Newcastle–Ottawa Scale, OS overall survival, PFS progression-free survival, RFS recurrence-free survival, RT-PCR reverse transcription-polymerase chain reaction, UVA univariate analysis